ArticleForensic science, medicine, and pathology2026
Serum S100B level as biomarker of traumatic deaths: correlations with injury patterns and postmortem interval.
Article in Forensic science, medicine, and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
S100B is a calcium-binding protein primarily found in astrocytes and Schwann cells. Accurate estimation of post-mortem interval is vital for reconstructing death timelines and guiding law enforcement. Similarly, precise determination of cause of death serves both legal and medical purposes, aiding judicial outcomes and informing public health strategies. This study aimed to assess serum S100B levels in trauma-related deaths, focusing on head and extracranial injuries, and their variation with postmortem intervals. Serum samples were collected from eighty subjects, including forty trauma cases with head and extracranial injuries and forty non-traumatic controls. Serum S100B concentrations were measured and statistically compared between trauma-related deaths and non-traumatic controls. S100B levels were also measured across different postmortem intervals (0, 6, 12, 24, 48, and 60 h). The current study showed that there was a significant increase in S100B levels in the study group (trauma-related deaths) compared to the control group, with a p-value < 0.001, and no significant differences between head and extracranial causes of death. There was also a significant elevation in S100B concentrations from 0 to 6 h postmortem (p < 0.001). After 6 h post-mortem, several S100B measurements exceeded the assay's upper reportable limit (4000 ng/L), limiting precise quantification beyond this range. In conclusion, post-mortem serum S100B demonstrates potential as a supplementary tool for early post-mortem interval estimation and differentiating trauma-related deaths, regardless of head injury involvement. However, values beyond 12 h post-mortem exceed assay detection limits, highlighting the need for extended measurement ranges in forensic applications.
Indexed as
Identifiers
42521978What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.